WASHINGTON (AP) -- An analysis by U.S. regulators says Johnson & Johnson's single-dose vaccine protects against COVID-19.

The report Wednesday confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19.

On Friday, a panel of experts to the Food and Drug Administration will debate if the evidence is strong enough to recommend the long-anticipated shot. The FDA is expected to make a final decision within days.

If the FDA clears the J&J shot for U.S. use, it won't boost vaccine supplies significantly right away. Only a few million doses are expected to be ready for shipping in the first week.

Get our free mobile app

Emerging Players with the Minnesota Timberwolves

More From KBUL NEWS TALK 970 AM & 103.3 FM